X4 Pharmaceuticals, Inc Income Statement
XFOR|6 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
X4 Pharmaceuticals, Inc reported $0 in revenue and $101M in net loss for FY2025. Revenue decreased 14.3% from FY2018 to FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3.0M | $0 | $0 | $3.5M |
| Cost of Revenue | $0 | $0 | - | - | - | - |
| SG&A Expense | $35.5M | $27.0M | $20.9M | $17.6M | $8.7M | $6.5M |
| R&D Expense | $72.0M | $61.1M | $41.9M | $30.2M | $20.3M | $17.8M |
| Operating Income | -$107.5M | -$87.6M | -$59.9M | -$51.7M | -$29.1M | -$24.3M |
| Interest Expense | - | - | $2.7M | $2.1M | $720.0K | $2.5M |
| Income Tax | $78.0K | $28.0K | $148.0K | $0 | $0 | - |
| Net Income | -$101.2M | -$93.9M | -$62.1M | -$52.8M | -$33.3M | -$23.0M |
| EPS (Basic) | -$17.07 | -$1.52 | -$3.09 | - | - | - |
| EPS (Diluted) | -$17.07 | -$1.52 | -$3.09 | -$4.63 | -$79.15 | -$44.79 |
| Shares Outstanding | 5.7M | 167.4M | 28.1M | 16.3M | 16.1M | 14.3M |
| Operating Margin | - | - | -1995.8% | - | - | -695.6% |
| Profit Margin | - | - | -2071.0% | - | - | -656.4% |